3450 L ± /L and the ratio of Leukemia cell was ± % ± 6. 5 % 10 ± 2 %. After 14 days infusion it was ± 1. 3

Size: px

Start display at page:

Download "3450 L ± /L and the ratio of Leukemia cell was ± % ± 6. 5 % 10 ± 2 %. After 14 days infusion it was ± 1. 3"

张羊纪
7 years ago
Views:

1 3449 mir L1210 田晓琳许亚梅王珍珍赖宗浪张雅月林英张冬梅孙波赵勇 mir L1210 mir L1210 mir L1210 DBA /2N A B C 100% A B C ± d ± d ± d ± /L ± /L ± /L ± % ± 6. 5 % ± 2. 0 % ± /L ± /L ± /L ± % ± % ± % mir L1210 DBA /2 mir L mir17-92 L mir Comparative study on mouse L1210 leukemia model with higher expression of mir established by different ways TIAN Xiao-lin * WANG Zhen-zhen ZHANG Ya-yue LAI Zong-lang LIN Ying ZHANG Dong-mei SUN Bo ZHAO Yong XU Ya-mei. * Department of Oncology and Hematology Dongzhimen Hospital Beijing University of Chinese Medicine Beijing China Corresponding author XU Ya-mei xuyamei@ sina. com Abstract Objective To make a comparative study of biological characteristics of a transferable mouse L1210 leukemia model with higher expression of mir inoculated by tail intravenous injection and hypodermic inoculation in order to select the best inoculation method that fits in with the bionomics of L1210 cells and has a better consistency. Methods B-leukemia cell line L1210 was conventionally infused into each DBA /2N mouse through the vena caudalia at the cellular concentration of A group at the cellular concentration of B group and subcutis at the cellular concentration of in the initial part of right leg C group. The process of leukemia in these mice was investigated. The amount of peripheral leucocytes in mouse blood was counted and the morphological changes were investigated. The liver spleen kidney and lung of the dying mice were kept weighed and made into pathological sections. Results The rate of tumorigenesis was 100% in each group. The average survival time of the three groups was ± d ± d ± d. The amount of peripheral leucocytes increased remarkably after 7 days infusion was ± /L ± / DOI /cma. j. issn mirna xuyamei@ sina. com

2 3450 L ± /L and the ratio of Leukemia cell was ± % ± 6. 5 % 10 ± 2 %. After 14 days infusion it was ± /L ± /L ± /L and the ratio was ± % ± % ± %. Leukemia cells could be found in peripheral blood smears of the three groups. In pathological Sections of the liver and spleen of dying mice diffused leukemia cell infiltration could be observed accompanied by destruction to the normal tissue and structure. A small quantity of leukemia cells was found in lungs and kidneys. The destruction to their normal tissue and structure was not obvious and hemorrhage was easily seen in lungs. Conclusions Inoculation of L1210 cells with higher expression of mir into DBA /2N mice through the vena caudalia or subeufis is feasible for developing a mouse leukemia model and the method of vena caudalia fits in with the bionomics of L1210 cells and has a better consistency. By tail intravenous injection the survival time in tumor is short and not apt for long time experiment observation. By hypodermic injection the survival time in tumor is long and tumor nodules are visible and apt for long time experiment observation but the ratio of lymphoma cell was not high. Key words Model leukemia Inoculation method mir L1210 cells in mice L1210 B L L1210 mir L L1210 DMEM mir L ml DMEM + 1 ml DMEM + 3 ~ 4 1. B 5 min 800 r /min L1210 ATCC 5 min CCL-219 mir μl L ~ 10 DBA /2 mir L ~ 24 g ± g ± x 珋 ± s 2. mir L1210 DBA /2 3 DBA /2 6 3 L /ml / A / B / C 3. L cm cm cm 6 d 4. 1 A B C 0. 1 ~ 0. 2 ml EDTA B P < r /min SPSS % ± d ± d ± d C A C B C EDTA P < C

3 mir L1210 x 珋 ± s d g A ± a ± b B ± ± b C ± a ± B a P < C b P < g /L x 珋 ± s Z P A ± ± ± B ± ± C ± ± ± Z P A B /L x 珋 ± s B Z P 15 A 1011 ± ± ± P < Z P P < P < P < ~ 5 4. A B mir L L C 2. 6 cm 2. 2 cm /L x 珋 ± s Z P A ± ± ± B ± ± C ± ± ± Z P B ± ± C ± ± ± % x 珋 ± s L1210 B Z P mir-17-92cluster A ± ± ± mir B ± ± mir L1210 C ± ± ± B Z P L A B C ± % ± % ± 5. 2 % A C B C P < CD45 CD19 CD3 CD mir L1210

4 % / / /L DBA /2 171 g /L L1210 EDTA mir L ~ 0. 2 ml L / / 2 mir L % / 2 4 8% ~ 11 ~ 16 d

5 ± d ± d ± d % 7Canti G 2 2 min mir L1210 DBA /2N mir L / mir L Jackson H 1Pouillart P Huong TH Lhéritier J. L 1210 leukemia an experimental model for the potentiation of drugs used for acute leukemias. Bull Cancer Morton DB. Advances in refinement in animal experimentationover past 25 years. Altern Lab Anim He L Thomson JM HemannMT et al. A microrna polycistron as a potentialhuman oncogene. Nature L L Sirotnak FM Moccio DM Dorick DM. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res Franco P Marelli O et al. Hematoporphyrin derivative rescue from toxicity caused by chemotherapy or radiation in a murine leukemia model L1210. Cancer Res Aldred AJCha MCMeckling-Gill KA. Determination of a humane endpoint in the L1210 model of murine leukemia. Contemp Top Lab Anim Sci Katarzyna K Rafal K Tomasz W et al. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'- deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clinical Cancer Research Pan XQ Lee RJ. In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model. Anticancer Res. L Jackson NC Bock M et al. Testicular relapse in acute lymphoblastic leukaemia studies with an experimental mouse model. Br J Cancer JAKI /STAT Roday LH Renoir JM Marsaud V et al. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Mol Pharm Dionet CA Rapp M Tchirkov A. Comparisons of carboplatin and cisplatin as potentiators of 5-fluorouracil and radiotherapy in the mouse L1210 leukaemia model. Anticancer Res 田晓琳, 许亚梅, 王珍珍, 等. 尾静脉注射及皮下接种方法建立小鼠高表达 mir 的 L1210 白血病模型的比较研究 [J /CD]. 中华临床医师杂志 : 电子版,2013,7( 8) :

21 13 D / 2 10 ig ig 10 d 1. 0 g kg /2 2 β- 5 g kg g kg mg kg - 1 ig ig 24 h 5% 1 2% CMC-Na 2. 5 ml 30

21 13 D / 2 10 ig ig 10 d 1. 0 g kg /2 2 β- 5 g kg g kg mg kg - 1 ig ig 24 h 5% 1 2% CMC-Na 2. 5 ml 30 21 13 1 2 1* 2 1. 430065 2. 445000 20 10 5 g kg - 1 5 mg kg - 1 ig 10 d ig HE 1 TFF1 TFF1 P < 0. 01 P < 0. 01 P < 0. 01 P < 0. 05 R285. 5 doi 10. 13422 /j. cnki. syfjx. 2015130100 A 1005-9903 2015 13-0100-05